Clotilde Brisbois
YOU?
Author Swipe
View article: Corrigendum to ‘Impact of asundexian on a panel of coagulation assays’[Research and Practice in Thrombosis and Haemostasis 9(5) (2025) 102950]
Corrigendum to ‘Impact of asundexian on a panel of coagulation assays’[Research and Practice in Thrombosis and Haemostasis 9(5) (2025) 102950] Open
View article: Impact of asundexian on a panel of coagulation assays
Impact of asundexian on a panel of coagulation assays Open
Despite this study including a comprehensive panel of coagulation assays, asundexian may still affect other coagulation assays not assessed here. Further investigations in patients treated with asundexian are therefore warranted.
View article: GFAP, UCH-L1, TAU AND NFL as potential biomarkers for glioblastoma diagnosis and monitoring: A retrospective study
GFAP, UCH-L1, TAU AND NFL as potential biomarkers for glioblastoma diagnosis and monitoring: A retrospective study Open
View article: Corrigendum to “Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?” [Thromb. Res. 236 (2024) 236–239 TR_8963]
Corrigendum to “Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?” [Thromb. Res. 236 (2024) 236–239 TR_8963] Open
View article: Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure?
Asundexian in atrial fibrillation: Can pharmacodynamic data explain the failure? Open